Jianmin Pharmaceutical GroupLtd Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Jianmin Pharmaceutical GroupLtd wird ein jährliches Gewinn- und Umsatzwachstum von 22.2% bzw. 12.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 22.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 21.5% betragen.

Wichtige Informationen

22.2%

Wachstumsrate der Gewinne

22.2%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	18.7%
Wachstumsrate der Einnahmen	12.3%
Zukünftige Eigenkapitalrendite	21.5%
Analystenabdeckung	Low
Zuletzt aktualisiert	22 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Potential Upside For Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) Not Without Risk

Nov 10

If EPS Growth Is Important To You, Jianmin Pharmaceutical GroupLtd (SHSE:600976) Presents An Opportunity

Sep 25

Calculating The Fair Value Of Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)

Aug 25

The Market Doesn't Like What It Sees From Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Earnings Yet As Shares Tumble 27%

Jul 12

We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt

Jun 30

We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease

May 21

We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings

Apr 26

Gewinn- und Umsatzwachstumsprognosen

SHSE:600976 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	5,393	749	N/A	740	1
12/31/2025	4,894	638	N/A	248	1
12/31/2024	4,446	533	N/A	549	1
9/30/2024	3,977	428	91	206	N/A
6/30/2024	4,061	508	156	245	N/A
3/31/2024	4,170	521	214	284	N/A
12/31/2023	4,213	521	204	268	N/A
9/30/2023	3,948	508	221	287	N/A
6/30/2023	3,965	472	131	212	N/A
3/31/2023	3,736	419	196	270	N/A
12/31/2022	3,641	408	148	216	N/A
9/30/2022	3,503	363	96	152	N/A
6/30/2022	3,344	326	203	254	N/A
3/31/2022	3,376	324	37	88	N/A
12/31/2021	3,299	305	192	248	N/A
9/30/2021	3,456	279	197	253	N/A
6/30/2021	3,221	258	130	175	N/A
3/31/2021	2,857	199	127	175	N/A
1/1/2021	2,456	148	80	126	N/A
9/30/2020	2,013	144	94	149	N/A
6/30/2020	2,154	93	14	83	N/A
3/31/2020	2,164	83	11	81	N/A
1/1/2020	2,239	91	5	74	N/A
9/30/2019	2,402	82	-32	35	N/A
6/30/2019	2,199	80	-12	41	N/A
3/31/2019	2,183	79	27	73	N/A
1/1/2019	2,161	81	21	64	N/A
9/30/2018	2,188	91	51	92	N/A
6/30/2018	2,311	100	N/A	130	N/A
3/31/2018	2,625	102	N/A	93	N/A
12/31/2017	2,712	91	N/A	35	N/A
9/30/2017	2,748	81	N/A	72	N/A
6/30/2017	2,677	71	N/A	54	N/A
3/31/2017	2,315	59	N/A	41	N/A
12/31/2016	2,364	65	N/A	114	N/A
9/30/2016	2,495	69	N/A	87	N/A
6/30/2016	2,430	80	N/A	21	N/A
3/31/2016	2,449	83	N/A	2	N/A
12/31/2015	2,281	86	N/A	48	N/A
9/30/2015	1,953	86	N/A	49	N/A
6/30/2015	1,860	102	N/A	130	N/A
3/31/2015	1,748	114	N/A	107	N/A
12/31/2014	1,753	116	N/A	103	N/A
9/30/2014	1,685	118	N/A	56	N/A
6/30/2014	1,716	108	N/A	56	N/A
3/31/2014	1,867	98	N/A	89	N/A
12/31/2013	1,992	96	N/A	45	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 600976Das prognostizierte Gewinnwachstum (22.2% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 600976Die Erträge des Unternehmens (22.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (26.1% pro Jahr).

Hohe Wachstumserträge: 600976Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 600976Die Einnahmen des Unternehmens (12.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (13.8% pro Jahr).

Hohe Wachstumseinnahmen: 600976Die Einnahmen des Unternehmens (12.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 600976Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (21.5%)

Jianmin Pharmaceutical GroupLtd Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Potential Upside For Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) Not Without Risk

Third quarter 2024 earnings released: EPS: CN¥0.54 (vs CN¥1.07 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Jianmin Pharmaceutical Group Co.,Ltd. to Report Q3, 2024 Results on Oct 19, 2024

Investor sentiment improves as stock rises 24%

If EPS Growth Is Important To You, Jianmin Pharmaceutical GroupLtd (SHSE:600976) Presents An Opportunity

Calculating The Fair Value Of Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)

The Market Doesn't Like What It Sees From Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Earnings Yet As Shares Tumble 27%

We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt

Jianmin Pharmaceutical Group Co.,Ltd. to Report First Half, 2024 Results on Aug 16, 2024

We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease

We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings

First quarter 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.65 in 1Q 2023)

Jianmin Pharmaceutical Group Co.,Ltd. to Report Q1, 2024 Results on Apr 20, 2024

Jianmin Pharmaceutical Group Co.,Ltd., Annual General Meeting, Apr 08, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 16%

Jianmin Pharmaceutical Group Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 16, 2024

Jianmin Pharmaceutical Group Co.,Ltd. to Report First Half, 2023 Results on Aug 16, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 16%

No independent directors

Third quarter 2022 earnings released: EPS: CN¥0.84 (vs CN¥0.59 in 3Q 2021)

Investor sentiment improved over the past week

Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) intends to acquire Zhejiang Huafang Medical Care Co., Ltd from Holley Group Company Limited, Zhejiang Holley Investment Management Co., Ltd. and Suzhou Yuanyi Zhiyuan Equity Investment Partnership (Limited Partnership) for CNY 15.2 million.

Second quarter 2022 earnings released: EPS: CN¥0.73 (vs CN¥0.64 in 2Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.59 (vs CN¥0.45 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.64 (vs CN¥0.25 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.12 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥0.60 in FY 2019)

Jianmin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 16, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: CN¥24.68

Third quarter earnings released

Jianmin Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 21, 2020

New 90-day high - CN¥25.64

First half earnings released

Jianmin Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 13, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken